Drug
Alvocidib clinical trials
Also written HMR 1275, L-868275 and flavopiridol.
- studies test it
- 49
- open now
- 0
- in phase 3
- 0
- first study started
- 1997
How studies write it
Studies that test it under each name
Studies by the year they started
49 studies that test it; most in 2004 (7)
| Year | Studies |
|---|---|
| 1997 | 2 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 5 |
| 2003 | 4 |
| 2004 | 7 |
| 2005 | 2 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 29
- Phase 2
- 24
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 44
National Cancer Institute (NCI) (38) · Sumitomo Pharma America, Inc. (3) · NCIC Clinical Trials Group (3) · AbbVie (1) · Gynecologic Oncology Group (1) · SWOG Cancer Research Network (1) · Sanofi (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Cytarabine (5) · Mitoxantrone (5) · Irinotecan (4) · Fluorouracil (3) · Gemcitabine (3) · Venetoclax (2) · Cisplatin (2) · Vorinostat (2)
Studies
Open first, then newest update. How each study uses alvocidib is read from its arms, and is right about nine times in ten.
Testing it · 49
- Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).CompletedPhase 1Sumitomo Pharma America, Inc.NCT03298984Written as Alvocidib
- Alvocidib Biomarker-driven Phase 2 AML StudyTerminatedPhase 2Sumitomo Pharma America, Inc.NCT02520011Written as Alvocidib
- Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapyTerminatedPhase 2Sumitomo Pharma America, Inc.NCT03969420Written as Alvocidib (flavopiridol) and cytarabine (Ara-C)
- A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedPhase 1AbbVieNCT03441555Written as Alvocidib
- Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnPhase 1/2M.D. Anderson Cancer CenterNCT04493099Written as Alvocidib Hydrochloride
- Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell LymphomaCompletedPhase 2NCIC Clinical Trials GroupNCT00005074Written as alvocidib
- Flavopiridol in Treating Patients With Metastatic Malignant MelanomaCompletedPhase 2NCIC Clinical Trials GroupNCT00005971Written as alvocidib
- Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedPhase 2NCIC Clinical Trials GroupNCT00005974Written as alvocidib
- Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or MediastinumTerminatedPhase 1National Cancer Institute (NCI)NCT00094978Written as Flavopiridol (alvocidib)
- Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00795002Written as alvocidib
- Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00445341Written as Flavopiridol
- Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT01349972Written as alvocidib
- Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic LymphomaCompletedPhase 1/2National Cancer Institute (NCI)NCT00058240Written as alvocidib
- Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedPhase 2National Cancer Institute (NCI)NCT00098371Written as alvocidib
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT00112723Written as alvocidib
- Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedPhase 1National Cancer Institute (NCI)NCT01076556Written as Alvocidib Hydrochloride
- Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00407966Written as alvocidib
- Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT00634244Written as alvocidib
- Flavopiridol in Treating Patients With Refractory CancerCompletedPhase 1National Cancer Institute (NCI)NCT00019344Written as alvocidib
- Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedPhase 1National Cancer Institute (NCI)NCT00735930Written as Alvocidib Hydrochloride
See all 49 studies that test alvocidib →
Given in every arm · 4 — alvocidib is usual care beside what is tested
- A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid LeukemiaCompletedPhase 1Sumitomo Pharma Co., Ltd.NCT03563560Written as Alvocidib
- Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell TumorsCompletedPhase 2National Cancer Institute (NCI)NCT00957905Written as Alvocidib Hydrochloride
- Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute LeukemiaCompletedPhase 1/2National Cancer Institute (NCI)NCT00016016Written as alvocidib
- Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00007917Written as alvocidib
Codes
What other systems call alvocidib · ClinicalTrials.gg INT003677
- MeSH (NLM) C077990alvocidibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 45AD6X575GALVOCIDIBConfirmed FDA, NLM, Wikidata
- Wikidata Q4063441alvocidibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74940AlvocidibOne source FDA
- DrugBank DB03496One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C077990 | alvocidib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 45AD6X575G | ALVOCIDIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4063441 | alvocidib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74940 | Alvocidib | One source FDA |
| DrugBank | DB03496 | — | One source Wikidata |
Also registered as alvocidib hydrochloride (UNII D48MS3A6N9).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.